In Situ Hybridization Market – Industry Trends and Global Forecast to 2024

SUBSCRIBE FOR UPDATED REPORTS

Get great contents delivered straight to your inbox everyday, just a click away, Sign Up Now.
Name
Email
US : +1-888-387-2818
UK : +44 208 089 1725

Global In Situ Hybridization Market – Industry Trends and Forecast to 2024

Global
Upcoming Reports
In-Situ Hybridization Market
  • No of pages :
    350
  • No of Figures:
    50
  • No of Tables:
    250
  • Report Type:
    Upcoming

Global In Situ Hybridization Market By Product (Fluorescent In Situ Hybridization, Chromogenic In Situ Hybridization), By Application (Cell Biology Research, Neuroscience, Oncology and Others), By End-User (Pharma And Biotechnology Laboratories, Research And Academics, Hospitals, Others), By Geography (North America, Europe, Asia-Pacific, Europe, South America, Middle East and Africa) – Industry Trends and Forecast to 2024

Market Analysis: Global In Situ Hybridization Market

The In Situ Hybridization Market accounted to USD 550.0 million in 2016 growing at a CAGR of 5.4% during the forecast period of 2017 to 2024. The upcoming market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.

Market Definition: Global In Situ Hybridization Market

The In situ Hybridization is a powerful technique for localizing specific nucleic acid targets within fixed tissues and cells which helps in obtaining spatial information about gene expression.

Major Market Drivers and Restraints:

  • Increasing prevalence of cancer disease
  • Increasing diagnosis of cancer disease
  • Advancement in therapeutics technology
  • Rising government initiatives
  • Increasing demand of accurate prognostic tools
  • Increasing healthcare expenditure

Market Segmentation: Global In Situ Hybridization Market

By product type the In situ Hybridization market is segmented into Flurocent In-Situ Hybridization (FISH) and Chromogenic In-Situ Hybridization (CISH). Flurocent In-Situ Hybridization is further segmented into DNA – FISH and RNA – FISH. Chromogenic In-Situ Hybridization is further segmented into DNA – CISH and RNA – CISH.

By application the market is segmented into cell biology research, neuroscience, oncology, others.

On the basis of end user the market is segmented into pharma and biotechnology laboratories, research and academics, hospitals and others.

On the basis of geography, In situ Hybridization market report covers data points for 28 countries across multiple geographies such as North America & South America, Europe, Asia-Pacific, and Middle East & Africa. Some of the major companies covered in this report are Agilent Technologies, Thermo Fisher Technologies, Affymetrix, Abbot Laboratories, Vector Laboratories, Inc., Advanced Cell Diagnostics, Nordic BioSite AB, Abcam Plc, Genemed Biotechnologies, Inc., Sigma-Aldrich Co. LLC, BioVisible BV, PerkinElmer Inc., Abnova Corporation, Enzo Life Sciences Inc., Bio SB, Elchrom Scientific AG among other companies.

Competitive Analysis: Global In Situ Hybridization Market

In situ Hybridization market is highly fragmented and is based on new product launches and clinical results of products. Hence the major players have used various strategies such as new product launches, clinical trials, market initiatives, high expense on research and development, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of In situ Hybridization market for global, Europe, North America, Asia Pacific and South America.

Major Market Competitors: Global In Situ Hybridization Market

Some of the major players operating in In situ Hybridization market are Medtronic (Ireland), General Electric Company, Siemens AG, Brainlab AG,  Koninklijke Philips NV, IMRIS Deerfield Imaging, NeuroLogica Corporation, Ziehm Imaging GmbH, Toshiba Corporation, Shimadzu Corporation, Neurologica Corporation, Imris Inc. among others.

Research Methodology: Global In Situ Hybridization Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more Please Request Analyst Call or drop down your enquiry.

Demand Side Primary Contributors: Doctors, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Choose Licence Type

Enterprise, Single User

1. INTRODUCTION

      1.1. OVERVIEW OF THE IN-SITU HYBRIDIZATION MARKET

      1.2. MARKET SEGMENTATION & COVERAGE

2. RESEARCH METHODOLOGY

      2.1. KEY TAKEAWAYS

      2.2. ARRIVING AT THE IN-SITU HYBRIDIZATION MARKET SIZE

              2.2.1. MARKET CRACKDOWN APPROACH

              2.2.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS

              2.2.3. KEY DATA POINTS FROM PRIMARY SOURCE

              2.2.4. KEY DATA POINTS FROM SECONDARY SOURCE

      2.3. ASSUMPTIONS

3. MARKET LANDSCAPE SUMMARY

4. MARKET OVERVIEW

      4.1. OVERVIEW

      4.2. IN-SITU HYBRIDIZATION MARKET: KEY PRIMARY INSIGHTS

      4.3. DRIVERS, OPPORTUNITIES AND THREAT ANALYSIS MATRIX

      4.4. KEY MARKET FINDINGS

      4.5. NEW REGULATORY POLICIES

5. IN-SITU HYBRIDIZATION MARKET, BY PRODUCT TYPE

      5.1. OVERVIEW

      5.2. IN-SITU HYBRIDIZATION MARKET, BY PRODUCT TYPE

              5.2.1. FLUROCENT IN-SITU HYBRIDIZATION (FISH)

                         5.2.1.1. DNA – FISH

                         5.2.1.2. RNA – FISH

              5.2.2. CHROMOGENIC IN-SITU HYBRIDIZATION (CISH)

                         5.2.2.1. DNA – CISH

                         5.2.2.2. RNA – CISH

6. IN-SITU HYBRIDIZATION MARKET, BY APPLICATION

      6.1. OVERVIEW

      6.2. CELL BIOLOGY RESEARCH

      6.3. NEUROSCIENCE

      6.4. ONCOLOGY

      6.5. OTHERS

7. IN-SITU HYBRIDIZATION MARKET, BY END-USER

      7.1. OVERVIEW

      7.2. PHARMA AND BIOTECHNOLOGY LABORATORIES

      7.3. RESEARCH AND ACADEMICS

      7.4. HOSPITALS

      7.5. OTHERS

8. IN-SITU HYBRIDIZATION MARKET, BY GEOGRAPHY

      8.1. COUNTRYWISE IN-SITU HYBRIDIZATION MARKET BY PRODUCT TYPE, APPLICATION, END-USER)

              8.1.1. NORTH AMERICA

                         8.1.1.1. U.S.

                         8.1.1.2. CANADA

                         8.1.1.3. MEXICO

              8.1.2. EUROPE

                         8.1.2.1. GERMANY

                         8.1.2.2. FRANCE

                         8.1.2.3. U.K.

                         8.1.2.4. ITALY

                         8.1.2.5. SPAIN

                         8.1.2.6. REST OF EUROPE

              8.1.3. ASIA-PACIFIC (APAC)

                          8.1.3.1. JAPAN

                         8.1.3.2. CHINA

                         8.1.3.3. SOUTH KOREA

                          8.1.3.4. INDIA

                         8.1.3.5. AUSTRALIA

                         8.1.3.6. REST OF APAC

              8.1.4. REST OF THE WORLD

                         8.1.4.1. BRAZIL

                         8.1.4.2. OTHERS

      8.2. KEY INSIGHTS: BY COUNTRY

9. EUROPE URINALYSIS MARKET: COMPETITIVE LANDSCAPE

      9.1. IN-SITU HYBRIDIZATION MARKET: COMPANY SHARE ANALYSIS

      9.2. NORTH AMERICA IN-SITU HYBRIDIZATION MARKET: COMPANY SHARE ANALYSIS

      9.3. EUROPE IN-SITU HYBRIDIZATION MARKET: COMPANY SHARE ANALYSIS

      9.4. AMERICA IN-SITU HYBRIDIZATION MARKET: COMPANY SHARE ANALYSIS

      9.5. MERGERS & ACQUISITIONS

      9.6. NEW PRODUCT DEVELOPMENT & APPROVALS

      9.7. EXPANSIONS

      9.8. REGULATORY CHANGES

      9.9. PARTNERSHIP AND OTHER STRATEGIC DEVELOPEMENTS

10. IN-SITU HYBRIDIZATION MARKET, COMPANY PROFILES

      10.1. ABBOTT

              10.1.1. OVERVIEW

              10.1.2. SWOT ANALYSIS

              10.1.3. PRODUCT PORTFOLIO

              10.1.4. REVENUE ANALYSIS

              10.1.5. ANALYSTS VIEW

      10.2. AGILENT TECHNOLOGIES

              10.2.1. OVERVIEW

              10.2.2. SWOT ANALYSIS

              10.2.3. PRODUCT PORTFOLIO

              10.2.4. REVENUE ANALYSIS

              10.2.5. ANALYSTS VIEW

      10.3. ADVANCED CELL DIAGNOSTICS (ACD)

              10.3.1. OVERVIEW

              10.3.2. SWOT ANALYSIS

              10.3.3. PRODUCT PORTFOLIO

              10.3.4. REVENUE ANALYSIS

              10.3.5. ANALYST VIEW

      10.4. AFFYMETRIX INC.

              10.4.1. OVERVIEW

              10.4.2. SWOT ANALYSIS

              10.4.3. PRODUCT PORTFOLIO

              10.4.4. REVENUE ANALYSIS

              10.4.5. ANALYSTS VIEW

      10.5. F. HOFFMANN-LA ROCHE LTD

              10.5.1. OVERVIEW

              10.5.2. SWOT ANALYSIS

              10.5.3. PRODUCT PORTFOLIO

              10.5.4. REVENUE ANALYSIS

              10.5.5. ANALYSTS VIEW

      10.6. THERMO FISHER SCIENTIFIC INC.

              10.6.1. OVERVIEW

              10.6.2. SWOT ANALYSIS

              10.6.3. PRODUCT PORTFOLIO

              10.6.4. REVENUE ANALYSIS

              10.6.5. ANALYSTS VIEW

      10.7. SIGMA ALDRICH CO. LLC.

              10.7.1. OVERVIEW

              10.7.2. SWOT ANALYSIS

              10.7.3. PRODUCT PORTFOLIO

              10.7.4. REVENUE ANALYSIS

              10.7.5. ANALYSTS VIEW

      10.8. VECTOR LABORATORIES, INC.

              10.8.1. OVERVIEW

              10.8.2. SWOT ANALYSIS

              10.8.3. PRODUCT PORTFOLIO

              10.8.4. REVENUE ANALYSIS

              10.1.5. ANALYSTS VIEW

      10.9. NORDIC BIOSITE AB

              10.9.1. OVERVIEW

              10.9.2. SWOT ANALYSIS

              10.9.3. PRODUCT PORTFOLIO

              10.9.4. REVENUE ANALYSIS

              10.9.5. ANALYSTS VIEW

      10.10. ABCAM PLC

              10.10.1. OVERVIEW

              10.10.2. SWOT ANALYSIS

              10.10.3. PRODUCT PORTFOLIO

              10.10.4. REVENUE ANALYSIS

              10.10.5. ANALYSTS VIEW

      10.11. GENEMED BIOTECHNOLOGIES, INC.

              10.11.1. OVERVIEW

              10.11.2. SWOT ANALYSIS

              10.11.3. PRODUCT PORTFOLIO

              10.11.4. REVENUE ANALYSIS

              10.11.5. ANALYSTS VIEW

      10.12. BIOVISIBLE BV

              10.12.1. OVERVIEW

              10.12.2. SWOT ANALYSIS

              10.12.3. PRODUCT PORTFOLIO

              10.12.4. REVENUE ANALYSIS

              10.12.5. ANALYSTS VIEW

      10.13. BIO SB

              10.13.1. OVERVIEW

              10.13.2. SWOT ANALYSIS

              10.13.3. PRODUCT PORTFOLIO

              10.13.4. REVENUE ANALYSIS

              10.13.5. ANALYSTS VIEW

      10.14. ABNOVA CORPORATION

              10.14.1. OVERVIEW

              10.14.2. SWOT ANALYSIS

              10.14.3. PRODUCT PORTFOLIO

              10.14.4. REVENUE ANALYSIS

              10.14.5. ANALYSTS VIEW

      10.15. ENZO LIFE SCIENCES INC.

              10.15.1. OVERVIEW

              10.15.2. SWOT ANALYSIS

              10.15.3. PRODUCT PORTFOLIO

              10.15.4. REVENUE ANALYSIS

              10.15.5. ANALYSTS VIEW

      10.16. ELCHROM SCIENTIFIC AG

              10.16.1. OVERVIEW

              10.16.2. SWOT ANALYSIS

              10.16.3. PRODUCT PORTFOLIO

              10.16.4. REVENUE ANALYSIS

              10.16.5. ANALYSTS VIEW

Available on Request.

Available on Request.

Please fill in the below form and our sales representatives will get back to you.

Thank You

Thank You

`